98453-81-7

Basic information

• Product Name: 2,5-furandione,3-(broMoMethyl)-4-Methyl
• Synonyms: 2,5-furandione,3-(broMoMethyl)-4-Methyl
• CAS NO: 98453-81-7
• Molecular Formula: C₆H₅BrO₃
• Molecular Weight: 205.0061
• Mol File: 98453-81-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,5-furandione,3-(broMoMethyl)-4-Methyl(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-furandione,3-(broMoMethyl)-4-Methyl(98453-81-7)
• EPA Substance Registry System: 2,5-furandione,3-(broMoMethyl)-4-Methyl(98453-81-7)

Safety Data

• Hazardous Substances Data: 98453-81-7(Hazardous Substances Data)

Usage

General Description

2,5-furandione,3-(broMoMethyl)-4-Methyl is a chemical compound with the molecular formula C7H7BrO3. It is an organic compound with a furan ring and two carbonyl groups. The bromomethyl and methyl groups are attached to the furan ring, contributing to its structure and properties. This chemical is commonly used in organic synthesis and as a building block for more complex compounds. It may also have potential applications in the pharmaceutical and agrochemical industries. However, due to its chemical structure and properties, it should be handled and used with care to prevent any potential hazards or environmental impact.

Upstream product

• 766-39-2 2,3-Dimethylmaleic anhydride 

Downstream Products

• 3552-33-8 2-ethyl-3-methylmaleic anhydride 
• 487-66-1 2-propionic-3-methylmaleic anhydride 
• 245124-18-9 3-Hydroxymethyl-4-methylfuran-2,5-dione 
• 488-20-0 buta-1,3-diene-2,3-dicarboxylic acid 
• 150240-39-4 chaetomellic anhydride A 
• 75052-75-4 3-Hexyl-4-methylfuran-2,5-dione 

Relevant articles and documents

Protein-drug conjugate programmed by pH-reversible linker for tumor hypoxia relief and enhanced cancer combination therapy

Combining functional proteins with small molecular drugs into one entity may endow distinct synergistic advantages. However, on account of completely different physicochemical properties of such payloads, co-delivery through systemic administration for therapeutic purpose is challenging. Herein, we designed the protein-drug conjugate HSAP-DC-CAT (human serum albumin/Pt (IV)-dibenzocyclooctyne/chlorin e6-catalase) by modification of CAT and cisplatin pro-drug loaded HSA with pH-sensitive azide linker 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) followed by click chemistry assembly with DC. The dynamic covalent bonds between linker and proteins, on the one hand, can bridge proteins and small molecular drugs in the intermediate state for systemic delivery in the harsh in vivo environment; on the other hand, it can trigger traceless cleavage and release of drugs and proteins with full bioactivity in acidic microenvironment of tumor. The multifunctional HSAP-DC-CAT provides efficient cytosolic transduction in vitro, excellent blood half-lives after systemic administration, and significant antitumor outcome via integrated cisplatin-based chemotherapy and Ce6-based photodynamic therapy enhanced by catalase-induced manipulation of tumor hypoxia microenvironment. This study describes a universal formulation strategy for protein and small molecular drug by a bifunctional linker through amide reaction and click chemistry, with traceless in vivo release of therapeutic units.

SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY

Provided herein are methods of using substituted azole dione compounds for treatment of viral infections.

Benzylic brominations with N-bromosuccinimide in (Trifluoromethyl)benzene

A variety of benzylic brominations were performed by using N-bromosuccinimide in (trifluoromethyl)benzene with photochemical activation in the presence of 2,2′-azobisisobutyronitrile, 1,1′- azobis(cyclohexanecarbonitrile), or benzoyl peroxide as the radical initiator. This system provides clean, rapid, and high-yielding reactions with replacement of conventional solvents, such as tetrachloromethane, by less-toxic (trifluoromethyl)benzene. Georg Thieme Verlag Stuttgart.